Retatrutide has shown greater efficacy in weight loss research than any previous generation of incretin-based peptides, with studies reporting double-digit percentage reductions in body mass
My skin has even gotten better
These findings point to new directions for treatment, offering hope to those affected by eating disorders. The article also discusses the need for further investigation of GLP-1 medication misuse as an eating disorder symptom and describes cognitive-behavioral therapy as a first-line treatment for bulimia and related disorders
The Bottom Line for Serious Researchers The question where to get retatrutide is ultimately a question about research integrity
76%) ( p 50 years have increased odds of advanced fibrosis due to MASLD even after adjustment for covariates [68]
As of January this year, California, New Hampshire, Pennsylvania and South Carolina ended Medicaid GLP-1 drug coverage for weight loss, and Michigan started restricting coverage to people classified as morbidly obese, meaning they have a body mass index above 40
